SUMMARY
 Medicare's Contractor (MolDX) is proposing a policy that would block access to personalized breast cancer risk tests that help women and their breast cancer doctors decide whether breast radiation will help them. These biomarker tests, DCISionRT® and Oncotype Dx DCIS®, have been extensively validated, and are used by thousands of breast cancer physicians and have impacted 50,000+ women with stage 0 breast cancer known as Ductal Carcinoma In Situ (DCIS). If this policy passes, women will lose access to personalized testing and be pushed into outdated, one-size-fits-all treatment, meaning they will continue to be overtreated with radiation therapy. We demand CMS withdraw this dangerous draft policy now.

Women Deserve Choices, Not Control

This draft Medicare MolDx policy is more than bureaucratic overreach — it's an insult to every woman who wants a say in her own care. It's 2025. Women don’t need protection from information. We need access to tools that help us and our doctors make informed decisions — especially after a Stage 0 breast cancer diagnosis.

What’s So Wrong With This Policy?

 1.  It Blocks Personalized Care

These tests are not “yes or no” decisions. They give personalized risk scores that guide treatment. Doctors use them to tailor radiation — sometimes to avoid it, sometimes to ensure it’s not missed. This policy ignores how these tests work.  Prior to the draft policy, a Medicare advisory panel of cancer experts reviewed these tests and said they agree these tests help avoid unnecessary treatments, lower costs, and support shared decision-making. DCISionRT’s ten peer-reviewed studies back this up.

So why is MolDx ignoring the experts, the science, and the voice of the patient?

 Please click here  to view the transcript of the experts call from July 2024 where they voted 6/7 in favor of the clinical evidence and the use of biomarker testing. This was not only ignored but misrepresented by MolDx in the proposed policy.

2. It Endangers Patients

 Traditional risk assessment tools, which have been used for the last 25 years, focus on pathology factors like tumor grade and size. While some DCIS may appear to be low risk, 20% will have aggressive tumors. These tests provide critical information and identify hidden threats. The biomarker tests provide new and better information to ensure that patients can make personalized decisions based on their biology.  

3. It Reverses Existing Coverage

This isn’t just about new tests. The policy would also revoke coverage for Oncotype DX® DCIS, a test Medicare has covered since 2017. What will Medicare rip away from women next?

4. It Applies a Dangerous Double Standard

 MolDx has already approved breast cancer tests with less evidence. But now, it’s demanding a new arbitrary standard and trying to tell the breast cancer doctors how to practice medicine. Does the pathologist at MolDx perform breast cancer surgery, provide radiation therapy, or treat breast cancer patients? No, no, and no. More importantly, why should DCIS breast cancer patients be denied access to evidence-based testing because of this double standard?

5. Why is Medicare ripping choice away from women?

 By removing these tests, Medicare isn’t just denying science — it’s denying women the right to participate in decisions about their own bodies.

What We’re Asking

•  Withdraw the draft LCD policy immediately
•  Hold all biomarker tests to the same fair, science-based standard
• Let women and their breast cancer doctors decide on their cancer care plan — not a pathologist at MolDx who has never treated a breast cancer patient

 Real Women. Real Doctors. Real Decisions.

Imagine facing breast cancer, knowing there is a test available to personalize your care, but being told it is no longer covered by insurance. 

Sign Now. Share Loudly.

This is about our bodies. Our treatment. Our future.

 Sign to protect access to personalized breast cancer care.
 Share this petition. Speak out. We will not go backward.

Want to do more?  Let your voice be heard, tell MolDX what you think.  Click here to see the draft policy and submit a comment to MolDx by August 28, 2025.